Thank you for your leadership in combatting the opioid epidemic. The undersigned organizations represent a diverse group of stakeholders across the health care spectrum committed to aligning 42 CFR Part 2 (Part 2) with the Health Insurance Portability and Accountability Act (HIPAA) for the purposes of treatment, payment, and health care operations (TPO).
AMCP joins over 100 stakeholder organizations calling for Congressional leadership to amend 42 CFR Part 2 to align with HIPAA in the compromise Opioid Package
AMCP Joins Over 100 Stakeholder Organizations Calling for Congressional Leadership to Amend 42 CFR Part 2 to Align with HIPAA in the Compromise Opioid Package.
AMCP supports the concept of collaborative drug therapy management (CDTM), a formal partnership between a pharmacist and a prescriber that allows the pharmacist to manage a patient’s drug therapy. CDTM, also referred to as collaborative practice, allows pharmacists to use their unique skills and abilities to complement other types of care provided by collaborating professionals to optimize patient outcomes.
September 2018 OVERVIEW AMCP is the nation’s leading professional association dedicated to increasing patient access to affordable medicines, improving health outcomes and ensuring the wise use of health care dollars. AMCP supports efforts to reduce drug prices by encouraging both meaningful transparency within health.
On September 10, 2018, AMCP submitted comments to CMS on its proposed revisions to the 2019 Physician Fee Schedule. While AMCP believes that a bundled episode of care payment is a step in the right direction to ensure patients with SUDs have access to care, AMCP provided CMS with several recommendations to consider when developing a formal proposal.